Table 6.
The top 10 co-cited references of targeted immunotherapy for MG.
| Rank | Title | Journal | Country | Author | Years | Number of citations |
|---|---|---|---|---|---|---|
| 1 | Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action | American Journal of Transplantation | USA | Pescovitz, MD | 2006 | 392 |
| 2 | Myasthenia gravis | Lancet | England | Vincent, A | 2001 | 359 |
| 3 | Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy | European Journal of Cancer | Germany | Zimmer, L | 2016 | 354 |
| 4 | Imbalance of regulatory T cells in human autoimmune diseases | Immunology | Austria | Dejaco, C | 2006 | 254 |
| 5 | Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study | Lancet Neurology | USA | Howard, JF | 2017 | 226 |
| 6 | Acetylcholine receptors and myasthenia | Muscle & Nerve | USA | Lindstrom, JM | 2000 | 202 |
| 7 | Long-lasting treatment effect of rituximab in MuSK myasthenia | Neurology | Spain | Diaz-Manera, J | 2012 | 194 |
| 8 | Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors | European Journal of Cancer | Australia | Makarious, D | 2017 | 146 |
| 9 | A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis | Muscle & Nerve | USA | Howard, JF | 2013 | 131 |
| 10 | Rituximab treatment of myasthenia gravis: a systematic review | Muscle & Nerve | USA | Tandan, R | 2017 | 121 |